A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia
NCT07681440
·
clinicaltrials.gov ↗
TERMINATED
Status
30
Enrollment
INDUSTRY
Sponsor class
Stopped
Insufficient enrollment
Conditions
Myelodysplastic Syndromes
Beta-thalassemia
Interventions
DRUG:
Luspatercept
Sponsor
Bristol-Myers Squibb